TRIB2 and prostate cancer: These findings indicate that TRIB2 is a new biomarker for NE-type prostate cancer and suggest that TRIB2 may contribute to enzalutamide resistance in prostate cancer cells, at least in part, by promoting lineage plasticity and phenotype switching.